EHA Unplugged

In this episode, Prof. Pieter Sonneveld is joined by Prof. Meletios Dimopoulos and Prof. Evangelos Terpos to discuss the updated EHA–EMN (European Myeloma Network) guidelines for the diagnosis, treatment and follow-up of multiple myeloma.  The conversation explores how recent therapeutic advances—including 14 newly approved treatment regimens, CAR T-cell therapies, bispecific antibodies and antibo...

Explore the latest advancements in immunotherapies for multiple myeloma, including CAR T-cell therapy, bispecific antibodies, and antibody-drug conjugates.  In this episode, Dr. Paula Rodriguez Otero discusses the strategic sequencing of BCMA and explains why CAR-T cells should often precede bispecific antibodies to maximize efficacy while  managing toxicity. The episode highlights the potential f...

Get up to date on menin inhibitors, an emerging class of targeted therapies for acute myeloid leukemia (AML). Menin is a key component of the KMT2A (lysine methyltransferase 2A, formerly MLL1) complex, which plays a critical role in gene regulation, development, and cell cycle control. Small-molecule menin inhibitors have shown particular promise in KMT2A-rearranged (KMT2Ar) and NPM1-mutated AML,...

Get up to date with the EHA–ESMO guidelines on Human immunodeficiency virus (HIV)-associated Lymphomas.  In this episode, Prof. Kai Hubel, a key author of the guidelines, explains the importance of having dedicated recommendations for patients with HIV-associated lymphomas. He begins by discussing the prevalence of lymphomas in people living with HIV, then highlights that the modern CART HIV treat...

Join Meritxell Alberich Jordà, an EHA Board member and a principal investigator from Prague, as she shares her journey to becoming a recognised research scientist in hematology, and the role EHA has played along the way. Her lab studies hematopoietic and leukemic stem cells, focusing on how disruptions in transcriptional regulation and inflammatory signalling drive the development and persistence...

Get up to date with the latest EHA Clinical Practice Guidelines for Large B-cell lymphoma (LBCL) ( ⁠ Large B‐cell lymphoma (LBCL): EHA Clinical Practice Guidelines for diagnosis, treatment, and follow‐up - Thieblemont - 2025 - HemaSphere - Wiley Online Library). ⁠   Prof Catherine Thieblemont and Prof Marie José Kersten, two key authors of the guidelines,  walk us through the recommendations for L...

In this episode of EHA Unplugged, patient advocate Peter Kapitein discusses the importance of connecting patients, researchers, and clinicians to accelerate cancer research and treatment. He shares insights from his work with Inspire2Live, focusing on collaboration, data ownership, affordability, and global access to innovative therapies.  Guest: Peter Kapitein Host: Isabel Olivera Martinez, PhD L...

Get up to date with the latest ESMO-EHA guideline for Peripheral T- and natural killer-cell lymphomas ( Peripheral T‐ and natural killer‐cell lymphomas: ESMO‐EHA Clinical Practice Guideline for diagnosis, treatment, and follow‐up - d'Amore - 2025 - HemaSphere - Wiley Online Library ) Prof Francesco D'Amore (Aarhus University, Denmark) and Prof Massimo Federico (University of Modena and Reg...

Join EHA President  Prof  Konstanze Döhner  from  University Hospital Ulm in Germany as she discusses her deep interest in hematology, both in research and in the clinics.   Listen as  Prof. Döhner shares why she decided to focus on Acute Myeloid Leukemia (AML) and myeloproliferative neoplasms (MPNs) in her career as a medical doctor, a researcher and a educator.  Tune in to hear  Prof. Döhner des...

In this episode, Dr Michael Milsom discusses how thehematopoietic system aging is a complex process with multiple causes. Dr Milsom proposes a more holistic view of the driving mechanisms of hematopoietic andimmune aging that does not focus solely on HSCs. He describes how inflammation‑driven stem cell activation and proliferation cause functional attrition and clonalselection of HSCs, contributin...

Get up to date with the latest EHA-EU guideline for Mantle Cell Lymphoma ( EHA–EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma - Jerkeman - 2025 - HemaSphere - Wiley Online Library ) with Prof Mats Jerkeman (Lund University, Sweden).   In this episode, he explains how biological risk factors, particularly  TP53  mutations and proliferation rate, inform patient stratif...

[This is a Rerelease. Episode first published on July 19, 2024.]Join us for a conversation with Jonathan Clark, a patient advocate who has been in remission for over five years after receiving CAR T-cell therapy for Mantle Cell Lymphoma. Jonathan shares his journey from relapse to recovery, detailing the challenges and triumphs of this cutting-edge treatment from a patient’s perspective. With host...

[This is a Rerelease. Episode first published on November 22, 2024.]Join us in this podcast episode to get a glimpse of what the future holds in the big field of innovation in hematology. With the help of our host, Dr Gregor Hormann (MLL Munich Leukemia Laboratory, Germany), you will be taken on a journey toward a future that is already here.    Dr Hormann will discuss the many potentials of AI in...

[This is a Rerelease. Episode first published on November 1, 2024.] Join us for an engaging episode with Dr. Stephen Hibbs from Queen Mary University of London as he discusses the environmental impacts of hematology. Alongside our host Dr. Sarah de Vlieger, they explore how climate change is already affecting hematology, emphasizing that these effects are being felt now rather than in the future....

[This is a Rerelease. Episode first published on April 11, 2025.] Listen to Dr. Jan Moritz Middeke from University Hospital in Dresden as he discusses the future of clinical trials in hematology and the role artificial intelligence (AI) may play in that field. Dr. Middeke explains how synthetic data is generated and what are the potential benefits and limitations of its use in clinical trials. He...

Join us for this interview with Dr Río-Machín from Autonomous University of Madrid in Spain as she discusses her research on rare subtypes of acute myeloid leukemia (AML), which she conducted thanks to the EHA Junior Research Grant. Her discovery of transcriptional activator of key leukemia drivers in one of these subtypes may pave way to new therapeutic approaches. Tune in to hear dr. Río-Machín‘...

Join us for this discussion between Prof Argiris Symeonidis from University of Patras in Greece and Prof Sam Salek from University of Hertfordshire in UK who focus on the role of the hematologist in the diagnosis and management of patients with Gaucher disease. Prof Symeonidis and Prof Salek are both experts in recognizing and treating this rare lysosomal storage disorder and share their recommend...

Join us for this inspiring interview with Erik Aerts from University Hospital Zurich in Switzerland and Mairéad Ní Chonghaile from St. James’s Hospital in Ireland who discuss their extensive work within the Hematology Nurses & Healthcare Professionals Group (HNHCP). Erik, the President, and Mairéad, the Vice-President of HNHCP, describe their unwavering commitment to providing hematology educa...

Join us for this inspiring interview with prof. Jesús San-Miguel from Clínica Universidad de Navarra in Spain who discusses his extensive work to improve care for patients with multiple myeloma. Prof San-Miguel’s research and clinical contributions have shaped the current treatment landscape for multiple myeloma. For his contributions, he has received the 2025 EHA Lifetime Achievement Award. Tune...

Join us for this interview with Dr Mandy Lauw from Erasmus Medical Center in Rotterdam, Netherlands who describes her work to increase the visibility and voice of young hematologists within the EHA. For her unwavering efforts to improve the support and opportunities for young hematologists at the beginning of their career, Dr Lauw has been awarded the Young EHA Award. Tune in to hear about the man...

Join us for this interview with Dr Ferran Nadeu Prat from August Pi i Sunyer Biomedical Research Institute in Barcelona, Spain who discusses his work on evolution of chronic lymphocytic leukemia (CLL), which he conducted thanks to the EHA Junior Research Grant. Dr Nadeu Prat explains how the new insights into CLL evolution toward Richter transformation, which is a lethal complication of CLL, may l...

Join us for this conversation with prof. Mariane de Montalembert from Necker-Enfants Malades Hospital in France who discusses the current standards of care for patients with sickle cell disease and thalassemia, both in Europe and in sub-Saharan Africa. Prof. de Montalembert highlights the inequalities and the unique challenges in implementation of complex innovative treatments, such as gene therap...

Join us for this inspiring interview with prof Béatrice Gulbis from The Brussels University Hospital in Belgium who discusses her extensive work on implementing neonatal screening for sickle cell disease (SCD) in low-resource countries in Africa. Prof Gulbis has been involved in collaborative projects to implement the testing methods that best fit the specific contexts. Tune in to hear her recomme...

Join us for this interview with dr. Côme Bommier from Saint-Louis Hospital in Paris, France who describes the results of the recent EHA survey on burnout symptoms among hematology professionals in Europe. Dr. Bommier discusses the findings of the survey in the context of modifiable systemic factors. Tune in to hear him urge organizational reforms to ensure better work environments for hematologist...

Join us for this inspiring conversation with prof. Anna Schuh from University of Oxford in the United Kingdom who describes her efforts to improve access to care for patients with hematological diseases in East African countries. Prof. Schuh describes the experience of sharing her time between the UK and East Africa and how this has impacted her clinical practice in both environments. Tune in to h...